Molecular chaperones and protein kinase quality control

Trends in Cell Biology

Volumn 17, Issue 2, 2007, Pages 87-92

  Caplan, Avrom J ^a   Mandal, Atin K ^a   Theodoraki, Maria A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN 37; CHAPERONE; ENZYME INHIBITOR; PROTEIN KINASE;

CHEMOTHERAPY; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME REGULATION; FUNCTIONAL PROTEOMICS; HUMAN; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW;

ADENOSINE TRIPHOSPHATE; ANIMALS; BENZOQUINONES; CATALYTIC DOMAIN; CELL CYCLE PROTEINS; CHAPERONINS; ENZYME ACTIVATION; HSP90 HEAT-SHOCK PROTEINS; HUMANS; HYDROLYSIS; LACTAMS, MACROCYCLIC; MAMMALS; MODELS, MOLECULAR; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN INTERACTION MAPPING; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP; YEASTS;

EID: 33846651282     PISSN: 09628924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcb.2006.12.002     Document Type: Review

References (47)

1. Frydman J. Folding of newly translated proteins in vivo: the role of molecular chaperones. Annu. Rev. Biochem. 70 (2001) 603-647
2. Whitesell L., and Lindquist S.L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 5 (2005) 761-772
3. Pratt W.B., and Toft D.O. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med. (Maywood) 228 (2003) 111-133
4. Arlander S.J., et al. Chaperoning checkpoint kinase 1 (Chk1), an Hsp90 client, with purified chaperones. J. Biol. Chem. 281 (2006) 2989-2998
5. Lee P., et al. Sti1 and Cdc37 can stabilize Hsp90 in chaperone complexes with a protein kinase. Mol. Biol. Cell 15 (2004) 1785-1792
6. Vaughan C.K., et al. Structure of an Hsp90-Cdc37-Cdk4 complex. Mol. Cell 23 (2006) 697-707
7. Pearl L.H., and Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machine. Ann. Rev. Biochem. 75 (2006) 271-294
8. Manning G., et al. The protein kinase complement of the human genome. Science 298 (2002) 1912-1934
9. Nolen B., et al. Regulation of protein kinases; controlling activity through activation segment conformation. Mol. Cell 15 (2004) 661-675
10. Huse M., and Kuriyan J. The conformational plasticity of protein kinases. Cell 109 (2002) 275-282
11. Akamine P., et al. Dynamic features of cAMP-dependent protein kinase revealed by apoenzyme crystal structure. J. Mol. Biol. 327 (2003) 159-171
12. Williams J.C., et al. The 2.35 A crystal structure of the inactivated form of chicken Src: a dynamic molecule with multiple regulatory interactions. J. Mol. Biol. 274 (1997) 757-775
13. Zhao Q., et al. Identification of a conserved sequence motif that promotes Cdc37 and cyclin D1 binding to Cdk4. J. Biol. Chem. 279 (2004) 12560-12564
14. Prince T., and Matts R.L. Definition of protein kinase sequence motifs that trigger high affinity binding of Hsp90 and Cdc37. J. Biol. Chem. 279 (2004) 39975-39981
15. Prince T., et al. Cdk2: a genuine protein kinase client of Hsp90 and Cdc37. Biochemistry 44 (2005) 15287-15295
16. Terasawa K., et al. Cdc37 interacts with the glycine-rich loop of hsp90 client kinases. Mol. Cell. Biol. 26 (2006) 3378-3389
17. Basso A.D., et al. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J. Biol. Chem. 277 (2002) 39858-39866
18. Chiosis G. Targeting chaperones in transformed systems-a focus on Hsp90 and cancer. Expert Opin. Ther. Targets 10 (2006) 37-50
19. Kamal A., et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425 (2003) 407-410
20. Kamal A., et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425 (2003) 407-410
21. Gooljarsingh L.T., et al. A biochemical rationale for the anticancer effects of Hsp90 inhibitors: Slow, tight binding inhibition by geldanamycin and its analogues. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 7625-7630
22. Xu W., et al. Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J. Biol. Chem. 276 (2001) 3702-3708
23. Xu W., et al. Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex. Nat. Struct. Mol. Biol. 12 (2005) 120-126
24. Tikhomirov O., and Carpenter G. Identification of ErbB-2 kinase domain motifs required for geldanamycin-induced degradation. Cancer Res. 63 (2003) 39-43
25. Citri A., et al. Hsp90 recognizes a common surface on client kinases. J. Biol. Chem. 281 (2006) 14361-14369
26. Bandhakavi S., et al. A positive feedback loop between protein kinase CKII and Cdc37 promotes the activity of multiple protein kinases. J. Biol. Chem. 278 (2003) 2829-2836
27. Shao J., et al. Phosphorylation of serine 13 is required for the proper function of the Hsp90 co-chaperone, Cdc37. J. Biol. Chem. 278 (2003) 38117-38120
28. Miyata Y., and Nishida E. CK2 controls multiple protein kinases by phosphorylating a kinase-targeting molecular chaperone, Cdc37. Mol. Cell. Biol. 24 (2004) 4065-4074
29. Sakagami M., et al. Benzoquinoid ansamycins (herbimycin A and geldanamycin) interfere with the maturation of growth factor receptor tyrosine kinases. Cell Stress Chaperones 4 (1999) 19-28
30. da Rocha Dias S., et al. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 65 (2005) 10686-10691
31. Grbovic O.M., et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 57-62
32. Wan P.T., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116 (2004) 855-867
33. Giannini A., and Bijlmakers M.J. Regulation of the Src family kinase Lck by Hsp90 and ubiquitination. Mol. Cell. Biol. 24 (2004) 5667-5676
34. Prince T., and Matts R.L. Exposure of protein kinase motifs that trigger binding of Hsp90 and Cdc37. Biochem. Biophys. Res. Commun. 338 (2005) 1447-1454
35. Yang J., et al. Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat. Struct. Biol. 9 (2002) 940-944
36. Stepanova L., et al. Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev. 10 (1996) 1491-1502
37. Jeffrey P.D., et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376 (1995) 313-320
38. Yang J., et al. Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol. Cell 9 (2002) 1227-1240
39. Taylor S.S., et al. PKA: a portrait of protein kinase dynamics. Biochim. Biophys. Acta 1697 (2004) 259-269
40. Castro J.E., et al. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. Blood 106 (2005) 2506-2512
41. McClellan A.J., et al. Folding and quality control of the VHL tumor suppressor proceed through distinct chaperone pathways. Cell 121 (2005) 739-748
42. Gusarova V., et al. Apoprotein B degradation is promoted by the molecular chaperones hsp90 and hsp70. J. Biol. Chem. 276 (2001) 24891-24900
43. Goasduff T., and Cederbaum A.I. CYP2E1 degradation by in vitro reconstituted systems: role of the molecular chaperone hsp90. Arch. Biochem. Biophys. 379 (2000) 321-330
44. Xu W., et al. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 12847-12852
45. Stepanova L., et al. Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia. Oncogene 19 (2000) 2186-2193
46. An W.G., et al. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ. 11 (2000) 355-360
47. Smith D.F., et al. Progesterone receptor structure and function altered by geldanamycin, an hsp90-binding agent. Mol. Cell. Biol. 15 (1995) 6804-6812